OspA: Difference between revisions
Ji Youn Park (talk | contribs) No edit summary |
Ji Youn Park (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
<applet load='1FJ1' size='500' frame='true' align='right' caption='OSPA.' scene= .'> | <applet load='1FJ1' size='500' frame='true' align='right' caption='OSPA.' scene= .'> | ||
OspA | <scene name='User:Ji_Youn_Park/1fj1_4_24-4/1'>OspA</scene> Outer surface protein A) is an abundant lipoprotein of the causative agent of Lyme disease, ''Borrelia burgdorferi'' spirochete. Its purpose is to stimulate the production of specific antibodies against ''B. burgdorferi'' and is used as a vaccination against Lyme disease, the disease carried by ticks("DrugBank: 2012). | ||
It is a borrelial protein that colonizes within the transmitting tick host midgut. Lyme disease is a progressive infection resulting from inoculation of the spirochete | It is a borrelial protein that colonizes within the transmitting tick host midgut. Lyme disease (blue link to wik) is a progressive infection resulting from inoculation of the spirochete ''B. burgdorferi'' into the skin by a feeding tick, usually species Ixodes ("Crystal Structure 2012). If left untreated, it may progress in many stages beginning from minor symptoms like rash, commonly seen as a bull-eyes rash and then progress into serious, lifelong disabilities. It is known to cause demyelinating diseases in the central nervous system (cite). One of the autoimmune process triggers, resulting in the demyelinating disease, occurs from the endurance of the Borrelia in the host. Once the spirochete is in the Central Nervous System, OspA is up-regulated for the sake of adhesion to the area (Durovska 2011). OspA is up-regulated when the protein is inside the transmitting tick host and begins down regulation upon infection of the mammalian host. Blockage of spirochete transmission from the tick vector to the mammalian host by anti-OspA antibodies appears to be the main mechanism of protection by the immunological response (de Silva 1996). However, further studies need to be done in order to improve the OspA based vaccines. | ||
Here, a 3-D prototype was created to portray its structures. OspA is composed of a prolonged fold with <scene name='User:Ji_Youn_Park/Beta_sheets/1'>21 anti-parallel Beta sheets</scene> and a single alpha helix. They are arranged to form the N-terminal, central sheet and C –terminal barrel domains OspA has numerous features, including a unique folding pattern that includes alternating charge arrays into antiparallel β-sheet, a potential ligand binding site, a conserved surface overlapping the epitope of the Fab, and a distinctive variable motif. It suggests that the protein has a conserved function, possibly acting as a receptor or signal transducer | |||
Here, a 3-D prototype was created to portray its structures. OspA is composed of a prolonged fold with <scene name='User:Ji_Youn_Park/Beta_sheets/1'>21 anti-parallel Beta sheets</scene> and a single alpha helix. They are arranged to form the N-terminal, central sheet and C –terminal barrel domains OspA has numerous features, including a unique folding pattern that includes alternating charge arrays into antiparallel β-sheet, a potential ligand binding site, a conserved surface overlapping the epitope of the Fab, and a distinctive variable motif. It suggests that the protein has a conserved function, possibly acting as a receptor or signal transducer ("Crystal Structure 2012). Although OspA normally has a lipidated N-terminal cysteine to provide a membrane anchor (Brandt 1990), a recombinant unlipidated form is soluble in aqueous solution and is still recognized by antibodies from Lyme disease patients (Dunn 1990). It was identified that three loops of connecting beta strands are the primary sites of binding. | |||